Cephalon Inc. v. Accord Healthcare Inc.
1:13-cv-02095
Overview
Parties
Defendant
Intas Pharmaceuticals Ltd. Operating Company
Represented By
1 Attorneys ListedSmith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Accord Healthcare Inc. Operating Company
Represented By
3 Attorneys ListedSmith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Plaintiff
Cephalon Inc. Operating Company
Represented By
6 Attorneys ListedGould & Ratner LLP
222 N. LaSalle Street, Suite 800
Bayard, P.A.
Bayard, P.A., 600 N. King Street
ADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN, (302) 655-5000
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi USA, LLC v. Cephalon, Inc.
AGILA SPECIALTIES INC. et al. v. Cephalon, Inc.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8445524
Solid forms of bendamustine hydrochloride
|
Filed: 2011-11-22
Issued: 2013-05-21
|
Active (5.0 yrs remaining)
Expires: 2031-11-22
|
|
|
US8436190
Bendamustine pharmaceutical compositions
|
Filed: 2006-01-12
Issued: 2013-05-07
|
Active (3.9 yrs remaining)
+1748d PTA
Expires: 2030-10-26
|
|
|
US8609863
Bendamustine pharmaceutical compositions
|
Filed: 2012-12-19
Issued: 2013-12-17
|
Active (6.1 yrs remaining)
Expires: 2032-12-19
|
|
|
US8791270
Bendamustine pharmaceutical compositions
|
Filed: 2013-08-19
Issued: 2014-07-29
|
Active (6.7 yrs remaining)
Expires: 2033-08-19
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
5
Dispositive
1
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings